The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | Novel immunotherapeutic strategies in lung cancer
Chongrui Xu, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, comments on the latest advances in immunotherapy for lung cancer. Chemotherapy with anti-PD-1 checkpoint inhibition has proven to be efficacious in patients with advanced non-small cell lung cancer (NSCLC) without driver mutations. For patients with a PD-L1 tumor proportion score of more than 50%, single agent immunotherapy is advised. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
